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The creation of vaccines for many different illnesses has now allowed humans to live in a
world where we are mostly burdened by non-communicable diseases due to lifestyle choices.
Although some vaccines have almost completely eradicated some illnesses, the influenza virus
continues to be a long lasting public health threat even though a vaccine has long since been
created for this virus. The history of influenza epidemics and pandemics are well documented as
these outbreaks can be traced back with some accuracy for the past three-hundred years (Potter,
2008). With this historical knowledge we have seen the devastation this virus can cause in
pandemics such as the Spanish Influenza outbreak of 1918 and even in outbreaks as recent as the
Swine Flu outbreak of 2009. As a result, study of the influenza virus is naturally significant and
important because this virus has the ability to cause high rates of illness and death in humans
regardless of how developed our society has become. The risk the influenza virus poses to
humans has caught the focus of many different fields of professionals including researchers,
epidemiologists, physicians, and the pharmaceutical industry as these groups of people have
generated a vast amount of literature and knowledge in regards to this topic (Potter, 2008). The
influenza virus has withstood the test of time by continuing to be a major public health problem
because this virus continues to have a major worldwide impact by causing serious illness, death,
and economic burden as a result of recurrent influenza epidemics that can be attributed to the
viral property of antigenic drift (Carrat & Flahault, 2007).Unlike bacteria or some other agents of
illness, the influenza virus has the ability to change its genetic code via antigenic drift which has
caused the emergence of many different strains of the virus. The implications of this ability are
significant to public health because being able to create different strains, some of which are
completely novel, means that humans can continuously be infected by the influenza virus even if
they have gotten this virus before as there is always the possibility of being infected by a new
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strain that the immune system does not recognize (Carrat & Flahault, 2007). Therefore there is a
critical need for continuously changing vaccination policies and available vaccines to keep up
with the evolution of the influenza virus, and there are institutions worldwide which were created
solely for this purpose. Each country has the liberty to handle their influenza vaccination policies
differently, but every vaccination program must have a measureable outcome. For the United
States the Advisory Committee on Immunization regularly updates why vaccination against
influenza is important, and most rationales argue that the influenza vaccine reduces factors like
hospital visits, mortality rates, and economic burden (Jefferson, 2006). In the United States there
seems to be a new trend where people are becoming distrustful of vaccination in general, but the
need for vaccination is crucial as the seasonal influenza vaccine is really our only protection
against this extremely dangerous virus. Therefore there is more pressure than ever to prove to
society that that influenza vaccine is important to public health and effective so the majority of
people will still be motivated to get their influenza vaccine each year. Encouraging the public to
get vaccinated against the influenza virus is not always an easy task as the influenza vaccine has
not always had the best reputation because some people think it is ineffective or will make them
sick. Unfortunately there is some truth to these reservations because some years the influenza
vaccine is not as effective as it was intended to be because there is not much human control over
how and when the prevalent influenza strains will evolve. The purpose of this paper is to
examine the efficacy of the influenza vaccine and its implication on vaccination policy as
maintaining or increasing vaccination efficacy is important to public health intervention against
this virus. To achieve this purpose a literature review will be conducted based on peer-reviewed
research to examine current vaccination policy, efficacy of the influenza vaccine, approaches to
improve efficacy, and the gap between vaccination policy and scientific evidence.
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International relations can sometimes be strained due to differences in ideology on many
issues, but current influenza vaccination policy is very much dependent on a collective
worldwide effort. All countries agree that the influenza virus is a danger to public health
worldwide especially in an era where there is so much international travel which heightens the
risk of quickly spreading illness like influenza. To get an idea of the scale of this worldwide
effort, currently there are 142 national influenza centers in 113 different countries which conduct
year-round surveillance for prevalent circulating influenza strains and disease trends (CDC,
2015). This part of the policy gives insight into influenza evolution because in terms of the
spread of the prevalent strains seasonally, each country cannot be treated as on isolated region
because geography plays an important role worldwide in which strains are most relevant at any
given time. With 142 contributing laboratories a vast amount of data is produced so in order to
come to a conclusion on which of the many influenza strains should be included in the vaccine
for each year the World Health Organization has five collaborating centers located in five
different countries which include the United States, United Kingdom, Australia, Japan, and
China (CDC, 2015). These five collaborating centers help narrow down the most prevalent
strains for each season, and ultimately the World Health Organization makes a worldwide
suggestion on which strains they feel should be included in each country’s seasonal influenza
vaccine. In the United States each seasonal flu vaccine protects against three or four strains of
the influenza virus based on the provided recommendations by the World Health Organization
and therefore our seasonal influenza vaccine is referred to as trivalent or tetravalent. The most
common circulating strains of influenza amongst humans today are Influenza A (H1N1),
Influenza A (H3N2), and Influenza B therefore these strains or variations of these strains are
usually included in the United States’ seasonal influenza vaccine (CDC, 2015). Although the
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CDC in Atlanta, Georgia is one of the World Health Organization’s collaboration centers, in the
United States the Food and Drug Administration makes the final decision on which vaccine
viruses to include in the seasonal flu shot by February of each year (CDC, 2015). Even though
the CDC does not make the final decision on the vaccine viruses, this organization is very
important because they report information on influenza activity in the United States each week
and conduct testing on the efficacy and ability of the seasonal flu shot to produce an immune
response against the influenza virus (CDC, 2015). Another important part of the United States’
current influenza vaccination policy is the prioritization of target populations for the seasonal
influenza vaccine. In general the CDC continues to recommend that everyone six months and
older should get vaccinated against the influenza virus, but the CDC does recognize that there are
certain high risks groups that are an even higher priority for vaccination. Some of these high
risks groups include adults 65 and older, young children six months to five years old, and
healthcare workers (Baguelin et al., 2013). As a result, many vaccination programs target these
high risk groups especially during seasons where vaccine availability is limited. Also the people
who are especially vulnerable to the influenza virus fall into high risks groups, and these high
risk groups are determined based on who will suffer the worst health complications from getting
the influenza virus. In the United States and other countries there is recognition that the influenza
vaccine is not always perfect and that vaccination programs do have limitations and do need to
be revamped from time to time. Therefore the CDC is very forthcoming with the limitations of
the seasonal influenza vaccine. Such as there are multiple factors which limit the influenza
vaccine and contributed to the vaccine’s efficacy which usually involve scientific issues and
timing limitations. Although there are many different strains of the influenza virus, the influenza
vaccine is limited by our scientific ability to be able to grow viable vaccine virus as vaccine
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viruses can only be grown in pathogen-free chicken eggs or canine kidney cells (CDC, 2015).
With these very specific criteria only certain vaccine viruses can be grown which means if a
vaccine virus for a prevalent strain cannot be grown successfully then humans will have to
remain unprotected. A large amount of a vaccine virus must be created in order for it to be
included in the vaccine therefore time constraints sometimes limit which vaccines can be grown
on time, and antigenic drift becomes a problem because even if antigenic drift is detected in
some cases there just is not enough time to grown a vaccine virus that matches a variant strain
which can be used in the vaccine (CDC, 2015). The importance of outlining the United States’
current influenza vaccination policy is to demonstrate how seriously this virus is taken from a
public health standpoint and how much effort, time, research, and money is put into creating the
best seasonal influenza vaccine possible. Although it is very true that much effort is put into
creating an influenza vaccine each year there still is room for improvement which makes
evaluating the efficacy of the influenza vaccine valuable as this can give insight into how
changes in policy could continue to increase the influenza vaccine’s protective power which
would benefit the humans population.
With the vast amount of influenza virus surveillance and research that is conducted yearround by many laboratories worldwide there are some key factors that have been identified
which are proven to decrease the efficacy of the influenza vaccine. The singlehanded most
important factor that decreases the efficacy of the influenza vaccine is the influenza virus’s
ability to undergo antigenic drift. The influenza virus would be simple to track and vaccinate
against if there was only one strain to target, but what makes the influenza virus so dangerous to
public health is that fact that antigenic drift causes mutations in the genetic code of the virus
which produces many different types of strains. Therefore when creating a vaccine for the
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influenza virus each year it is comparable to trying to hit a moving target because antigenic drift
allows the virus to change, and we can never be completely certain which strains will be most
prevalent each year. To put the problem of antigenic drift into perspective, it has been found that
antigenic drift is responsible for the global change in vaccine composition and since 1968
antigenic drift had caused the influenza vaccine composition to be updated approximately every
two to five years (Boni, 2008). Antigenic drift occurs as a means for the influenza virus to evade
human immunity even in vaccinated individuals so clearly this ability can decrease the
effectiveness of the influenza vaccine because the influenza virus is designed to change so that
the human immune system cannot recognize the virus (Moldoveanu et al., 1999). Research on
antigenic drift has provided information that suggests that antigenic drift occurs every two to
eight years due to evolutionary pressure, and antigenic drift can occur in all strains of the A and
B viruses (Kanai et al., 2010). On a biological level, changes to the genetic code of each viral
strain due to antigenic drift are subtle usually only involving a point mutation of one nucleotide
within antibody binding sites which occur at the hemagglutinin and neuraminidase viral proteins
on the surface of the virus (Boni, 2008). As a result small changes to the virus can cause a
significant impact on humans by causing an increased amount of illness and death by decreasing
the efficacy of the influenza vaccine with the emergence of variant strains. Also antigenic drift
causes varying evolutionary patterns as this type of biological change can causes the reemergence of old influenza strains or the creation of new variants (Boni, 2008). Overall it is
proven that antigenic drift can decrease the efficacy of the influenza vaccine, but the impact
varies between seasons based on when antigenic drift is most active. Next, vaccine strain
mismatching is related to and a consequence of antigenic drift and this is a factor which is also
known to decrease the efficacy of the influenza vaccine. In the United States production of the
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seasonal influenza vaccine can take up to nine months, and due to this lengthy production period
this gives the opportunity for antigenic drift to occur and a new prevalent strain of influenza can
arise while the vaccine is still in production. The consequence of this is that if a new strain arises
during this production period it would be too costly and there would not be enough time to
include this new strain in the vaccine that is being produced. Therefore reduce effectiveness of
the influenza vaccine and a potential for an epidemic can occur as one of the circulating strains
will not match one of the vaccine strains making the human immune system vulnerable (CDC,
2015). The last factor to be mentioned that decreased the efficacy of the influenza vaccine is herd
immunity which occurs when the majority of the human population is vaccinated against the
influenza virus. Herd immunity is significant because it is known that strong host immunity is
the driving force that causes antigenic drift to occur in the influenza virus (Boni, 2008).
Antigenic drift is triggered by strong herd immunity amongst a population because this causes
the circulating influenza viruses to have low evolutionary fitness which in turn favors mutations
to occur via antigenic drift. As a result mutations caused by antigenic drift increase the fitness of
the influenza virus and allow the virus to escape the herd immunity and cause illness (Boni,
2008). This relationship between herd immunity and antigenic drift means that increasing the
number of vaccinated individuals in a population increases herd immunity which in turn
increases antigenic drift. In terms of vaccination strategies, vaccinating too many people can
actually have negative consequences in terms of influenza virus evolution whereas vaccinating
fewer people or being more selective as to who should receive vaccination would increase
influenza vaccine efficacy by decreasing antigenic drift (Boni, 2008). Although it seems that
vaccinating fewer people would be advantageous this is an unrealistic solution to increase
efficacy because there is also danger in vaccinating fewer people, therefore it would be better to
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strengthen our influenza monitoring efforts during seasons where herd immunity is high in an
effort to recognize sooner when antigenic drift occurs so the human population can be warned
and take extra precautions. Typically in the United States the most vaccination for the influenza
virus occurs in October and November which makes herd immunity high at the beginning of the
flu season which in turn would make the emergence of variant influenza strains more likely to be
recognizable by the end of the same flu season so more monitoring efforts during this time
period would allow for earlier recognition of variant strains which could help improve the
vaccine for next season (Boni, 2008). In order to tie this section together it is important to note
that factors like vaccine strain mismatching and herd immunity are indirect factors that decrease
the efficacy of the influenza vaccine as these factors are either a cause or consequence of
antigenic drift which again is the main factor that decreases efficacy.
Within the scientific community concerned with the influenza vaccine and vaccination
policy it is undebated that the efficacy of the influenza vaccine can be decreased, but what is
debated is the best approaches to try to overcome the factors that can decrease the efficacy of the
influenza vaccine. Formerly mentioned in this paper were three major factors that are widely
known to negatively impact the efficacy of the influenza vaccine, and there are other less
significant or newly discovered factors that have not been addressed. With so many factors that
can possibly negatively impact the efficacy of the influenza vaccine there are many different
suggested approaches that try to overcome these factors in an effort to ensure and increase the
efficacy of the influenza vaccine. With so many laboratories and research worldwide dedicated
to study the influenza virus and vaccine, there is a vast amount of data related to efficacy of the
influenza vaccine that has to be sifted through and interpreted for future use. In this section of the
paper I will cite some of the most common and widespread approaches that are being discussed

10

within the scientific community currently based off of available research that has been
conducted. There is naturally a worldwide problem with decreased efficacy of the influenza
vaccine as this would make the human population more vulnerable to illness, therefore looking
into approaches that can maintain or increase the efficacy of the influenza vaccine is important
because the main goal of the influenza vaccine and vaccination programs is to protect as many
people from this virus as possible to decrease illness, death, and economic burden. As a result
there seems to be two categories of approaches that are predominate within current scientific
research, and these categories consist of either adapting vaccination policy and monitor efforts
for the influenza virus or making improvements to the content of the vaccine itself. Both
categories of approaches are valuable, and the first category of approaches to be discussed is
ones that suggest making adaptations to vaccination policy and monitoring efforts. One
suggested approach is to increase the use of sero-epidemiological testing which means to use
serum from human blood to better understand the incidence and distribution of disease (Kanai et
al., 2010). In the human immune response after receiving an influenza vaccine, the human body
makes antibodies against the influenza virus therefore conducting research on serum and
monitoring populations periodically could give better insight into how the body reacts to the
influenza virus and vaccine on a biological level (Moldoveanu et al., 1999). It is important to
note that the idea of conducting sero-epidemiological testing is not a new idea as mass
serological surveys worldwide are already done each year to help determine which strains should
be included in the vaccine, but what is new is the suggestion for better organizing and targeting
how this testing should be conducted (Kanai et al., 2010). Although there is mass serological
testing that is conducted each year a noticeable trend is that there is not much of this type of
testing conducted in tropical regions such as in Southeast Asian countries. Therefore it may be
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advantageous to the efficacy of the influenza vaccine and monitoring efforts if seroepidemiological is better allocated worldwide as the importance of this type of testing has been
confirmed by its mass usage annually (Kanai et al., 2010). The suggestion of better allocating
sero-epidemiological testing also alludes to the next approach to be discussed which is related to
geography. Such as it is well known that different parts of the world play different roles in
influenza virus evolution, therefore it is suggested that geographic considerations should be used
to better target and monitor the emergence of novel strains of influenza and the stains that are
most prevalent each year (Boni, 2008). Currently vaccine recommendations and strain
monitoring are done on a global scale, but increasing monitoring on a smaller more localized
scale can help indicate the regions that impact influenza virus evolution the most and target
regions where the most antigenic drift occurs (Boni, 2008). Also climate plays an important role
in peak influenza season and influenza virus evolution as influenza virus infection occurs
throughout the year in tropical regions whereas in temperate regions infection most occurs in the
winter season which is just one example of how geography can affect the influenza virus (Kanai
et al., 2010). One geographic consideration that is known and valued is that it is important to
have close monitoring for novel influenza variants in China and Southeast Asia, and this displays
how if more attention is paid to geographic considerations there is the possibility that influenza
monitoring can become more pointed and effective (Kanai et al., 2010). Another adaptation that
is worth mentioning in terms of modification to influenza vaccination policy is the consideration
to adjust target populations for influenza vaccination. Although the CDC recommends that
everyone six months and older should get vaccinated against influenza, many vaccination
programs target high risks groups like adults aged sixty-five and older or small children
especially when vaccine availability is limited. Targeting these high risks groups is beneficial
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because it offers protection to these groups by lowering the amount of illnesses and financial
burden, but targeting other groups of people may offer a broader range of protection. Such as,
children that are not young enough to be in the high risk category have been found to be the key
spreaders of the influenza therefore it could be more beneficial to target children not in the high
risk categories and the adults these children come in contact with in an effort to decrease the
spread of the influenza virus in the first place (Baguelin et al., 2013). Specifically it has been
found that the most optimal allocation of influenza vaccine would be to prioritize schoolchildren
and adults aged thirty to thirty-nine as children are the key spreaders of the influenza virus and
parents serve as a bridge to the rest of the population (Medlock & Galvani, 2009). Overall
changes to vaccination policy and monitoring efforts are probably the fastest and most efficient
routes to take in an effort to increase or maintain the efficacy of the influenza vaccine as changes
to the vaccine itself would require lengthy clinical trials and testing.
Now that approaches pertaining to vaccination policy and monitoring efforts have been
addressed, the next to be addressed are approaches pertaining to actual changes to the influenza
vaccine itself in an effort to increase or maintain the efficacy of the influenza vaccine. Again, the
approaches that will be discussed are the most current and prevalent in scientific research. In the
United States all seasonal influenza vaccines either contain three or four strains that are picked to
be included in each dose of the vaccine, but one approach to increasing or maintaining the
efficacy of the influenza vaccine is to add more strains to the vaccine. Adding more strains to the
vaccine would allow humans to be protected against a broader range of strains, but this approach
also has some disadvantages to it. Such as, adding more strains to the influenza vaccine could
make the vaccine too costly or make the production process too long. Also adding more strains
still would not guarantee that humans would be more protected if antigenic drift occurred.
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Although this approach is not perfect or foolproof, it relates to the idea behind the second
approach to be addressed which is cross protective vaccines. The idea behind cross protective
vaccines is the same as adding more strains to the influenza vaccine which is that cross
protective vaccines could reduce the impact of antigenic drift by helping the body make more
antibodies that can possibly protect the immune system against a broader range of influenza
strains and variant strains (Carrat & Flahault, 2007). Therefore cross protective vaccines could
provide more protection against the influenza virus than the regular seasonal influenza vaccine
could provide as cross protection can evoke an immune response that provides sufficient
protection against some strains even if the vaccine components are not optimally matched which
would be valuable to use during seasons where antigenic drift occurs (Heckler et al., 2006).
Humans can gain cross reactive antibodies from the seasonal influenza shot when variant strains
are somewhat similar to the strains included in the vaccine, but most importantly specific cross
protective vaccines could be made as a supplement and provide more protection during seasons
when a substantial amount of antigenic drift occurs and efficacy of the seasonal influenza
vaccine is lowered (Katz et al., 2009). The last approach to be addressed is the proposal for a
universal influenza vaccine which would completely change vaccination policy and eliminate the
need for a constantly changing seasonal influenza vaccine. Research is now moving in this
direction in search of a universal influenza vaccine because it would eliminate the problem of
antigenic drift, but currently a universal vaccine for the influenza virus remains in a preclinical
stage as much more research needs to be done (Carrat & Flahault, 2007). Hemagglutinin and
Neuraminidase are viral proteins on the surface of the virus which are the most antigenic
proteins, and the current seasonal influenza vaccine is based off of these proteins even though
Hemagglutinin and Neuraminidase are highly susceptible to antigenic drift (Carrat & Flahault,
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2007). Therefore the goal of universal vaccine would to make a vaccine based on more
conserved parts of the virus that are not heavily affected by antigenic drift so that the vaccine
would remain effective and not be negatively impacted by variant strains (Carrat & Flahault,
2007). Currently there has been research conducted on a part of the influenza virus called the M2
ion channel protein which is a more conserved part of the virus, and ultimately targeting proteins
like this would provide for protection across all strains of the influenza virus so there would be
no need to worry about decreased efficacy of the vaccine (Carrat & Flahault, 2007). In general a
lot more research needs to be conducted on improvement to the influenza vaccine itself, but
some of these approaches may have a promising future if research advances to a point where
these approaches are useable in creating an improved influenza vaccine for the human
population.
Many approaches that are suggested to increase or maintain the efficacy of the influenza
vaccine seem like valuable ideas which lead to the question as to why there is a gap between
actual influenza vaccination policy and scientific evidence. Besides the fact that new approaches
take time implement once they are deemed appropriate to use, there are multiple reasons why
there is a gap between vaccination policy and scientific evidence. One reason which contributes
to this gap is that many research studies only report data from one or two flu seasons which make
the data produced from these types of studies unreliable and difficult to interpret because the
circulation and incidence of the influenza virus varies greatly each year due to factors like
antigenic drift (Jefferson, 2006). Another factor that contributes to this gap is based on the scale
of each scientific study as studies with small numbers of participants or small data sets again
make the data produced unreliable due to the limited scope of the study (Jefferson, 2006).
Amongst other symptoms influenza is characterized as causing respiratory illness, and since
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there are many other illnesses that cause similar symptoms it is almost impossible to differentiate
actual influenza and influenza-like illness which in most cases is just considered to be influenza
when it really is not (Jefferson, 2006). The confusion between influenza and influenza-like
illness becomes problematic because it leads to an overestimation of the impact of influenza and
unrealistic expectations of the success of influenza vaccines which can be reflected in evidence
from scientific research as well (Jefferson, 2006). Besides these factors the integrity of the
studies that report scientific evidence must be thoroughly scrutinized as many studies are poorly
designed or biased which leads to confounders and inaccurate data that could never be used to
help determine or modify vaccination policy (Jefferson, 2006). Overall the gap between
vaccination policy and scientific evidence is justified because it is a lengthy process to extract
scientific evidence produced by researchers that has merit and is reliable enough to include in
vaccination policy. There may be pressure or temptation to use scientific evidence because it
sounds good or seems like a viable way to deal with the influenza problem, but policy makers
have to be very careful with which evidence they use because it would be a waste of resources
like time and money to use them on improper evaluation (Miller et al., 2009). Lastly, immediate
action always has to be taken against influenza in order to control this virus and hopefully there
can be closer collaborations and lessons drawn from previous knowledge so that policy makers
and researchers can possibly decrease the gap between policy and scientific evidence so that the
human population can benefit from the outcome (Miller et al., 2009).
The influenza virus is nondiscriminatory and is a worldwide public health problem
especially when pandemics and epidemics occur. Also the subject of the influenza virus is
complicated because there are so many factors and collaborations that occur in an attempt to
control this virus from causing illness and death. Hopefully this paper clarifies all the elements

16

that go into the public health intervention against the influenza virus, and above all indicates the
need for continuous adaptation of both policy and vaccine composition in order to combat a
continuously evolving virus that has historically been very dangerous to the human population
worldwide.
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